US supplies most of the world’s plasma. No country depends on it more than China

China’s Hidden Dependence on American Blood Plasma

Goldlaner.com – Behind the headlines about trade wars and semiconductor restrictions lies a quieter, more intimate dependency: millions of Chinese patients each year receive intravenous infusions of human albumin manufactured from plasma collected in the United States. The connection is not a matter of preference. It is the product of decades of regulatory caution, a national health catastrophe in the 1990s, and a domestic collection infrastructure that has never fully recovered. The result is a country that consumes more of the world’s most abundant plasma protein than any other, yet imports the overwhelming majority of its supply from its largest geopolitical rival.

A Mother’s Treatment, A Daughter’s Dilemma

In a small town in Henan province, central China, Ge Lan, 44, watched pale yellow fluid drip steadily into her mother’s vein. The woman, recovering from surgery for stomach cancer, required daily doses of imported human albumin to rebuild blood protein levels depleted by the procedure. Each 10-gram bottle carried a price tag of roughly $46 — the single most expensive item in her mother’s entire treatment regimen.

“I just hope (she) gets better soon. I’m worried about the money too, but I have no choice.”

Ge works in a local retail store. Over the two months of her mother’s recovery, 72 bottles were administered — a cost equivalent to seven months of her own earnings. Without financial help from a sister, she said the treatment simply could not have been paid for. And without it, her mother’s condition risked deteriorating further. The episode captures, in miniature, what happens when a national supply chain runs through a single foreign source: individual families absorb the shock.

The World’s Largest Albumin Market

Human albumin is the most plentiful protein found in blood plasma. Clinicians deploy it to manage critical trauma such as severe burns, to counter hypoproteinemia following major surgery, and to stabilize patients suffering from chronic liver disease and other conditions that erode circulating protein levels. China accounts for the largest share of global albumin consumption, yet its domestic plasma collection capacity has long fallen short of demand.

A 2024 study co-authored by researchers affiliated with China’s national drug inspection authority and its Zhejiang provincial counterpart found that more than 60 percent of the albumin sold in the Chinese market is produced by foreign manufacturers, and every unit of that imported product is derived from plasma collected in the United States. The United States itself supplies approximately 70 percent of the world’s plasma and stands among the very few nations that compensate donors for each donation.

American Donors Fueling a Foreign Medicine

On the supply side, the story belongs to ordinary Americans who trade a few hours of their time for cash that keeps the lights on. Sky Tucker, 25, a community college student, has donated plasma twice a week for seven years. The income helps cover rent, groceries, and the care of his cats.

“While I do know it could save a life, most of the time, I’m just worried about if I’m gonna get my next meal or if I can feed my cats.”

Millions of Americans participate in this routine each year. For Chinese patients, that routine translates directly into the availability of a life-sustaining medicine whose production is geographically locked to one country’s collection infrastructure.

The Scandal That Shaped a Decade of Shortfall

China’s current plasma-collection rules carry the imprint of a national trauma. In the mid-1980s, Beijing banned imports of nearly all blood products — with the sole exception of human albumin — amid escalating fears over the global HIV/AIDS crisis. The government then sought to build a domestic plasma-based industry from scratch.

In the impoverished province of Henan, local authorities pinned economic ambitions on the plasma trade, rallying hundreds of thousands of cash-strapped farmers to sell their plasma. A slogan circulated through villages in central China, captured in a 2004 report by The Beijing News, a state-run newspaper:

“Stretch your arm, show your veins; one stretch, one fist — 50 yuan earned.”

At the time, 50 yuan approximated a month’s income for many rural households. The frenzy, however, was built on unsafe and unsanitary practices — including the reuse of needles — that fueled one of China’s worst HIV outbreaks. Henan recorded its first HIV case in 1995, prompting authorities to shut down blood banks across the province. Nine years later, a 2004 provincial census reported by state broadcaster CCTV confirmed that 25,000 former plasma sellers in the province had contracted the virus. Independent investigators continued to document the scale of the disaster in subsequent years.

The scandal left a lasting regulatory scar. Plasma collection rules tightened dramatically, and the domestic supply base never rebuilt to the scale the market requires.

Beijing’s Push to Close the Gap

Government officials appear increasingly conscious of the vulnerability embedded in the current arrangement. Xi Chen, associate professor of Public Health at Yale University, noted that Beijing has moved to expand the capacity of plasma collection within the Chinese market.

“That’s why they wanted to enhance the capacity of collecting the plasma in the Chinese market.”

In 2023, dozens of newly licensed plasma collection centers opened across the country. Last July, regulators cleared the nation’s first rice-based albumin product for commercial sale — a plant-derived alternative intended to reduce dependence on animal-source plasma. These steps form part of a broader industrial policy aimed at shrinking the import gap.

Nonetheless, the shortfall persists. Industry data and estimates of domestic demand, as cited by Chinese state media, point to an annual deficit of roughly 6,000 tons of plasma — a gap that no near-term policy adjustment can close.

What Disruption Would Mean for Patients

Researchers have warned that the concentration of supply in one country creates a single point of failure. Geopolitical friction, a global health emergency of the kind seen during the Covid-19 pandemic, or a trade-policy shift could interrupt the flow of US-sourced plasma into Chinese manufacturing lines. In such a scenario, patients already dependent on daily albumin infusions — cancer survivors, burn victims, liver-disease patients — would face shortages and price spikes almost immediately.

For Ge Lan and the families like hers scattered across Henan and beyond, the abstraction of supply-chain risk resolves into a very concrete question: whether the next bottle arrives, and whether the money stretches far enough to buy it. Until domestic collection scales up and alternative sources mature, that question will remain unanswered for millions of patients each year.